Results 201 to 210 of about 188,535 (344)
Review article: new treatments in non‐alcoholic fatty liver disease [PDF]
Sarah Townsend, Philip N. Newsome
openalex +1 more source
Ferroptosis: The Demise of Cells Through Phospholipid Peroxidation
The relative abundance of peroxidation‐resistant monounsaturated fatty acids (MUFAs) vs. peroxidation‐sensitive polyunsaturated fatty acids (PUFAs) incorporated into phospholipid (PL) is a key determinant of ferroptosis sensitivity, as the peroxidation of PL PUFA acyl chains (PUFA‐PL) disrupts membrane integrity, causing ferroptotic cell death ...
Shaojie Cui, Jin Ye
wiley +1 more source
Investigating Factors Influencing Disease Progression in Patients With Non-Alcoholic Fatty Liver Disease. [PDF]
Tseng YC +4 more
europepmc +1 more source
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng +6 more
wiley +1 more source
Association Between Dietary Tea Consumption and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. [PDF]
Verma A, Sah R, Mehta R.
europepmc +1 more source
This review presents a process‐oriented framework for vascularized cardiac tissue engineering, highlighting how the coordinated design of cells, biomaterials, and biofabrication strategies enables the functional development or vascularized myocardium for disease modelling and drug discovery.
Yang Liu +9 more
wiley +1 more source
Non-alcoholic fatty liver disease: modern methods of diagnostics and treatment strategies
I. E. Kushnir
openalex +1 more source
Molecular characterization of the A52 murine hepatocellular carcinoma cell line
Hepatocellular carcinoma (HCC) is a poor outcome cancer with limited therapeutic choices. To advance therapeutic development we genetically characterized the A52 murine HCC cell line. We noted genetic changes that match a subset of human HCC and this offers the opportunity to test novel targeted therapies in syngeneic mice.
Rhys Gillman +5 more
wiley +1 more source
Diagnosis and Management of Pediatric Non-Alcoholic Fatty Liver Disease: An Overview. [PDF]
Dop D +5 more
europepmc +1 more source

